Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?

Gut Liver · 2022 · PMC8761931 · PMID 35027507

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

I assume that neoadjuvant therapy is a favorable trend for biologically borderline resectable disease in patients with anatomically resectable status. 10 Pancreatic cancer may be already micro-metastatic disease even in anatomically resectable status.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.